These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 33121950)

  • 1. Efficacy of the thromboxane receptor antagonist NTP42 alone, or in combination with sildenafil, in the sugen/hypoxia-induced model of pulmonary arterial hypertension.
    Mulvaney EP; Reid HM; Bialesova L; Mendes-Ferreira P; Adão R; Brás-Silva C; Kinsella BT
    Eur J Pharmacol; 2020 Dec; 889():173658. PubMed ID: 33121950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension.
    Mulvaney EP; Reid HM; Bialesova L; Bouchard A; Salvail D; Kinsella BT
    BMC Pulm Med; 2020 Apr; 20(1):85. PubMed ID: 32252727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treprostinil palmitil inhibits the hemodynamic and histopathological changes in the pulmonary vasculature and heart in an animal model of pulmonary arterial hypertension.
    Corboz MR; Plaunt AJ; Malinin V; Li Z; Gauani H; Chun D; Cipolla D; Perkins WR; Chapman RW
    Eur J Pharmacol; 2022 Feb; 916():174484. PubMed ID: 34508752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The thromboxane receptor antagonist
    Mulvaney EP; Renzo F; Adão R; Dupre E; Bialesova L; Salvatore V; Reid HM; Conceição G; Grynblat J; Llucià-Valldeperas A; Michel JB; Brás-Silva C; Laurent CE; Howard LS; Montani D; Humbert M; Vonk Noordegraaf A; Perros F; Mendes-Ferreira P; Kinsella BT
    Front Cardiovasc Med; 2022; 9():1063967. PubMed ID: 36588576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats.
    Lang M; Kojonazarov B; Tian X; Kalymbetov A; Weissmann N; Grimminger F; Kretschmer A; Stasch JP; Seeger W; Ghofrani HA; Schermuly RT
    PLoS One; 2012; 7(8):e43433. PubMed ID: 22912874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RP5063, a novel, multimodal, serotonin receptor modulator, prevents Sugen 5416-hypoxia-induced pulmonary arterial hypertension in rats.
    Bhat L; Hawkinson J; Cantillon M; Reddy DG; Bhat SR; Laurent CE; Bouchard A; Biernat M; Salvail D
    Eur J Pharmacol; 2017 Sep; 810():83-91. PubMed ID: 28576407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The selective PGI2 receptor agonist selexipag ameliorates Sugen 5416/hypoxia-induced pulmonary arterial hypertension in rats.
    Honda Y; Kosugi K; Fuchikami C; Kuramoto K; Numakura Y; Kuwano K
    PLoS One; 2020; 15(10):e0240692. PubMed ID: 33057388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension.
    Tang Y; Tan S; Li M; Tang Y; Xu X; Zhang Q; Fu Q; Tang M; He J; Zhang Y; Zheng Z; Peng J; Zhu T; Xie W
    BMC Pulm Med; 2022 Apr; 22(1):142. PubMed ID: 35413880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of mitochondrial fragmentation in microvascular endothelial cells isolated from the SU5416/hypoxia model of pulmonary arterial hypertension.
    Suresh K; Servinsky L; Jiang H; Bigham Z; Zaldumbide J; Huetsch JC; Kliment C; Acoba MG; Kirsch BJ; Claypool SM; Le A; Damarla M; Shimoda LA
    Am J Physiol Lung Cell Mol Physiol; 2019 Nov; 317(5):L639-L652. PubMed ID: 31461316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the FGF receptor-1 inhibitor, infigratinib, with or without sildenafil, in experimental pulmonary arterial hypertension.
    Felix NS; de Mendonça L; Braga CL; da Silva JS; Samary CDS; Vieira JB; Cruz F; Rocha NN; Zapata-Sudo G; Rocco PRM; Silva PL
    Br J Pharmacol; 2019 Dec; 176(23):4462-4473. PubMed ID: 31351013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptomic Analysis of Right Ventricular Remodeling in Two Rat Models of Pulmonary Hypertension: Identification and Validation of Epithelial-to-Mesenchymal Transition in Human Right Ventricular Failure.
    Park JF; Clark VR; Banerjee S; Hong J; Razee A; Williams T; Fishbein G; Saddic L; Umar S
    Circ Heart Fail; 2021 Feb; 14(2):e007058. PubMed ID: 33541093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fasudil Dichloroacetate Alleviates SU5416/Hypoxia-Induced Pulmonary Arterial Hypertension by Ameliorating Dysfunction of Pulmonary Arterial Smooth Muscle Cells.
    Liu P; Huang W; Ding Y; Wu J; Liang Z; Huang Z; Xie W; Kong H
    Drug Des Devel Ther; 2021; 15():1653-1666. PubMed ID: 33935492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. β3 adrenergic agonism: A novel pathway which improves right ventricular-pulmonary arterial hemodynamics in pulmonary arterial hypertension.
    Karimi Galougahi K; Zhang Y; Kienzle V; Liu CC; Quek LE; Patel S; Lau E; Cordina RL; Figtree GA; Celermajer DS
    Physiol Rep; 2023 Jan; 11(1):e15549. PubMed ID: 36597221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhaled combination of sildenafil and rosiglitazone improves pulmonary hemodynamics, cardiac function, and arterial remodeling.
    Rashid J; Nozik-Grayck E; McMurtry IF; Stenmark KR; Ahsan F
    Am J Physiol Lung Cell Mol Physiol; 2019 Jan; 316(1):L119-L130. PubMed ID: 30307312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of treprostinil in the SU5416-hypoxia model of severe pulmonary arterial hypertension: haemodynamic benefits are not associated with improvements in arterial remodelling.
    Chaudhary KR; Deng Y; Suen CM; Taha M; Petersen TH; Mei SHJ; Stewart DJ
    Br J Pharmacol; 2018 Oct; 175(20):3976-3989. PubMed ID: 30098019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paeoniflorin Ameliorates Chronic Hypoxia/SU5416-Induced Pulmonary Arterial Hypertension by Inhibiting Endothelial-to-Mesenchymal Transition.
    Yu M; Peng L; Liu P; Yang M; Zhou H; Ding Y; Wang J; Huang W; Tan Q; Wang Y; Xie W; Kong H; Wang H
    Drug Des Devel Ther; 2020; 14():1191-1202. PubMed ID: 32256050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nintedanib improves cardiac fibrosis but leaves pulmonary vascular remodelling unaltered in experimental pulmonary hypertension.
    Rol N; de Raaf MA; Sun XQ; Kuiper VP; da Silva Gonçalves Bos D; Happé C; Kurakula K; Dickhoff C; Thuillet R; Tu L; Guignabert C; Schalij I; Lodder K; Pan X; Herrmann FE; van Nieuw Amerongen GP; Koolwijk P; Vonk-Noordegraaf A; de Man FS; Wollin L; Goumans MJ; Szulcek R; Bogaard HJ
    Cardiovasc Res; 2019 Feb; 115(2):432-439. PubMed ID: 30032282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased MAO-A Activity Promotes Progression of Pulmonary Arterial Hypertension.
    Sun XQ; Peters EL; Schalij I; Axelsen JB; Andersen S; Kurakula K; Gomez-Puerto MC; Szulcek R; Pan X; da Silva Goncalves Bos D; Schiepers REJ; Andersen A; Goumans MJ; Vonk Noordegraaf A; van der Laarse WJ; de Man FS; Bogaard HJ
    Am J Respir Cell Mol Biol; 2021 Mar; 64(3):331-343. PubMed ID: 33264068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension.
    Chaumais MC; Djessas MRA; Thuillet R; Cumont A; Tu L; Hebert G; Gaignard P; Huertas A; Savale L; Humbert M; Guignabert C
    Cardiovasc Res; 2021 Apr; 117(5):1391-1401. PubMed ID: 32653925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the effects of RP5063, a novel, multimodal, serotonin receptor modulator, as single-agent therapy and co-administrated with sildenafil, bosentan, and treprostinil in a monocrotaline-induced pulmonary arterial hypertension rat model.
    Bhat L; Hawkinson J; Cantillon M; Reddy DG; Bhat SR; Laurent CE; Bouchard A; Biernat M; Salvail D
    Eur J Pharmacol; 2018 May; 827():159-166. PubMed ID: 29453947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.